223 related articles for article (PubMed ID: 16616639)
1. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance.
Krishna S; Woodrow CJ; Staines HM; Haynes RK; Mercereau-Puijalon O
Trends Mol Med; 2006 May; 12(5):200-5. PubMed ID: 16616639
[TBL] [Abstract][Full Text] [Related]
2. Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.
Haynes RK; Cheu KW; N'Da D; Coghi P; Monti D
Infect Disord Drug Targets; 2013 Aug; 13(4):217-77. PubMed ID: 24304352
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the contribution of the hemozoin synthesis pathway of the murine Plasmodium yoelii to the resistance to artemisinin-related drugs.
Witkowski B; Lelièvre J; Nicolau-Travers ML; Iriart X; Njomnang Soh P; Bousejra-Elgarah F; Meunier B; Berry A; Benoit-Vical F
PLoS One; 2012; 7(3):e32620. PubMed ID: 22403683
[TBL] [Abstract][Full Text] [Related]
4. Artemisinin antimalarials: mechanisms of action and resistance.
Meshnick SR
Med Trop (Mars); 1998; 58(3 Suppl):13-7. PubMed ID: 10212891
[TBL] [Abstract][Full Text] [Related]
5. Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity.
Garah FB; Stigliani JL; Coslédan F; Meunier B; Robert A
ChemMedChem; 2009 Sep; 4(9):1469-79. PubMed ID: 19645001
[TBL] [Abstract][Full Text] [Related]
6. A medicinal chemistry perspective on artemisinin and related endoperoxides.
O'Neill PM; Posner GH
J Med Chem; 2004 Jun; 47(12):2945-64. PubMed ID: 15163175
[No Abstract] [Full Text] [Related]
7. Expression in yeast links field polymorphisms in PfATP6 to in vitro artemisinin resistance and identifies new inhibitor classes.
Pulcini S; Staines HM; Pittman JK; Slavic K; Doerig C; Halbert J; Tewari R; Shah F; Avery MA; Haynes RK; Krishna S
J Infect Dis; 2013 Aug; 208(3):468-78. PubMed ID: 23599312
[TBL] [Abstract][Full Text] [Related]
8. Quinolines and artemisinin: chemistry, biology and history.
Bray PG; Ward SA; O'Neill PM
Curr Top Microbiol Immunol; 2005; 295():3-38. PubMed ID: 16265885
[TBL] [Abstract][Full Text] [Related]
9. Identification of an antimalarial synthetic trioxolane drug development candidate.
Vennerstrom JL; Arbe-Barnes S; Brun R; Charman SA; Chiu FC; Chollet J; Dong Y; Dorn A; Hunziker D; Matile H; McIntosh K; Padmanilayam M; Santo Tomas J; Scheurer C; Scorneaux B; Tang Y; Urwyler H; Wittlin S; Charman WN
Nature; 2004 Aug; 430(7002):900-4. PubMed ID: 15318224
[TBL] [Abstract][Full Text] [Related]
10. Pumped up: reflections on PfATP6 as the target for artemisinins.
Krishna S; Pulcini S; Moore CM; Teo BH; Staines HM
Trends Pharmacol Sci; 2014 Jan; 35(1):4-11. PubMed ID: 24268763
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
Uhlemann AC; Wittlin S; Matile H; Bustamante LY; Krishna S
Antimicrob Agents Chemother; 2007 Feb; 51(2):667-72. PubMed ID: 17145800
[TBL] [Abstract][Full Text] [Related]
12. Artemisinins and the biological basis for the PfATP6/SERCA hypothesis.
Krishna S; Pulcini S; Fatih F; Staines H
Trends Parasitol; 2010 Nov; 26(11):517-23. PubMed ID: 20638904
[TBL] [Abstract][Full Text] [Related]
13. Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.
Aponte S; Guerra ÁP; Álvarez-Larrotta C; Bernal SD; Restrepo C; González C; Yasnot MF; Knudson-Ospina A
Trans R Soc Trop Med Hyg; 2017 Feb; 111(2):71-80. PubMed ID: 28460112
[TBL] [Abstract][Full Text] [Related]
14. Artemisinin and chloroquine: do mode of action and mechanism of resistance involve the same protagonists?
Lelièvre J; Berry A; Benoit-Vical F
Curr Opin Investig Drugs; 2007 Feb; 8(2):117-24. PubMed ID: 17328227
[TBL] [Abstract][Full Text] [Related]
15. Artemisinins: mechanisms of action and potential for resistance.
Krishna S; Uhlemann AC; Haynes RK
Drug Resist Updat; 2004; 7(4-5):233-44. PubMed ID: 15533761
[TBL] [Abstract][Full Text] [Related]
16. Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins.
Cui L; Wang Z; Jiang H; Parker D; Wang H; Su XZ; Cui L
Antimicrob Agents Chemother; 2012 May; 56(5):2546-52. PubMed ID: 22354307
[TBL] [Abstract][Full Text] [Related]
17. Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin.
Parapini S; Basilico N; Mondani M; Olliaro P; Taramelli D; Monti D
FEBS Lett; 2004 Sep; 575(1-3):91-4. PubMed ID: 15388339
[TBL] [Abstract][Full Text] [Related]
18. K13, the Cytostome, and Artemisinin Resistance.
Xie SC; Ralph SA; Tilley L
Trends Parasitol; 2020 Jun; 36(6):533-544. PubMed ID: 32359872
[TBL] [Abstract][Full Text] [Related]
19. Biological actions of artemisinin: insights from medicinal chemistry studies.
Li J; Zhou B
Molecules; 2010 Mar; 15(3):1378-97. PubMed ID: 20335987
[TBL] [Abstract][Full Text] [Related]
20. Artemisone--a highly active antimalarial drug of the artemisinin class.
Haynes RK; Fugmann B; Stetter J; Rieckmann K; Heilmann HD; Chan HW; Cheung MK; Lam WL; Wong HN; Croft SL; Vivas L; Rattray L; Stewart L; Peters W; Robinson BL; Edstein MD; Kotecka B; Kyle DE; Beckermann B; Gerisch M; Radtke M; Schmuck G; Steinke W; Wollborn U; Schmeer K; Römer A
Angew Chem Int Ed Engl; 2006 Mar; 45(13):2082-8. PubMed ID: 16444785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
